ASCO 2025 Plenary: SERENA-6

Two Onc Docs
24/06/2025 12 min Temporada 4 Episodio 15
ASCO 2025 Plenary: SERENA-6

Listen "ASCO 2025 Plenary: SERENA-6"

Descargar episodio

Episode Synopsis

This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA